Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate for PVR in pediatric RRD
NCT04830878Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methotrexate in Proliferative Vitreoretinopathy (PVR), sponsored by Stanford University. Primary endpoint: Recurrence of Retinal Detachment at 6 months. Planned start Apr 2021; status: withdrawn.
02
Drugs
methotrexate
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT04830878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830878.